Neither was SOX2 expression associated with cancer-specific survival for stage II (HR = 0.83; 95%CI 0.40–1.69; p = 0.600; Figure 2C) nor stage III disease (HR = 0.91; 95%CI 0.59–1.40; p = 0.670; Figure 2D). The gene discussed is SOX2; the disease is cancer.